Literature DB >> 32933982

Targeting uric acid levels in treating gout.

Joey Ton1, Michael R Kolber2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32933982      PMCID： PMC7491671     

Source DB:  PubMed          Journal:  Can Fam Physician        ISSN： 0008-350X            Impact factor:   3.275


× No keyword cloud information.
  10 in total

1.  A randomised controlled trial of the efficacy and safety of allopurinol dose escalation to achieve target serum urate in people with gout.

Authors:  Lisa K Stamp; Peter T Chapman; Murray L Barclay; Anne Horne; Christopher Frampton; Paul Tan; Jill Drake; Nicola Dalbeth
Journal:  Ann Rheum Dis       Date:  2017-03-17       Impact factor: 19.103

2.  Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout.

Authors:  William B White; Kenneth G Saag; Michael A Becker; Jeffrey S Borer; Philip B Gorelick; Andrew Whelton; Barbara Hunt; Majin Castillo; Lhanoo Gunawardhana
Journal:  N Engl J Med       Date:  2018-03-12       Impact factor: 91.245

3.  Serum urate as surrogate endpoint for flares in people with gout: A systematic review and meta-regression analysis.

Authors:  Lisa Stamp; Melanie B Morillon; William J Taylor; Nicola Dalbeth; Jasvinder A Singh; Marissa Lassere; Robin Christensen
Journal:  Semin Arthritis Rheum       Date:  2018-02-21       Impact factor: 5.532

4.  Does starting allopurinol prolong acute treated gout? A randomized clinical trial.

Authors:  Erica M Hill; Karen Sky; Michelle Sit; Angelique Collamer; Jay Higgs
Journal:  J Clin Rheumatol       Date:  2015-04       Impact factor: 3.517

5.  Management of Acute and Recurrent Gout: A Clinical Practice Guideline From the American College of Physicians.

Authors:  Amir Qaseem; Russell P Harris; Mary Ann Forciea; Thomas D Denberg; Michael J Barry; Cynthia Boyd; R. Dobbin Chow; Linda L Humphrey; Devan Kansagara; Sandeep Vijan; Timothy J Wilt
Journal:  Ann Intern Med       Date:  2016-11-01       Impact factor: 25.391

Review 6.  A systematic review and meta-analysis on the safety and efficacy of febuxostat versus allopurinol in chronic gout.

Authors:  Labib I Faruque; Arash Ehteshami-Afshar; Natasha Wiebe; Lisa Tjosvold; Joanne Homik; Marcello Tonelli
Journal:  Semin Arthritis Rheum       Date:  2013-12       Impact factor: 5.532

7.  Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis.

Authors:  Gregory C Borstad; Leslie R Bryant; Michael P Abel; Daren A Scroggie; Mark D Harris; Jeff A Alloway
Journal:  J Rheumatol       Date:  2004-12       Impact factor: 4.666

8.  Comparison of drug adherence rates among patients with seven different medical conditions.

Authors:  Becky A Briesacher; Susan E Andrade; Hassan Fouayzi; K Arnold Chan
Journal:  Pharmacotherapy       Date:  2008-04       Impact factor: 4.705

Review 9.  Medication adherence among patients with gout: A systematic review and meta-analysis.

Authors:  Lieke E J M Scheepers; Marloes van Onna; Coen D A Stehouwer; Jasvinder A Singh; Ilja C W Arts; Annelies Boonen
Journal:  Semin Arthritis Rheum       Date:  2017-10-07       Impact factor: 5.532

10.  Efficacy and cost-effectiveness of nurse-led care involving education and engagement of patients and a treat-to-target urate-lowering strategy versus usual care for gout: a randomised controlled trial.

Authors:  Michael Doherty; Wendy Jenkins; Helen Richardson; Aliya Sarmanova; Abhishek Abhishek; Deborah Ashton; Christine Barclay; Sally Doherty; Lelia Duley; Rachael Hatton; Frances Rees; Matthew Stevenson; Weiya Zhang
Journal:  Lancet       Date:  2018-10-20       Impact factor: 79.321
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.